thymosin alpha-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Biko and several other black African NUSAS members were frustrated when it organised parties in white dormitories, which black Africans were forbidden to enter. In July 1967, a NUSAS conference was held at Rhodes University in Grahamstown; after the students arrived, they found that dormitory accommodation had been arranged for the white and Indian delegates but not the black Africans, who were told that they could sleep in a local church. Biko and other black African delegates walked out of the conference in anger. Biko later related that this event forced him to rethink his belief in the multi-racial approach to political activism:
== Use and effects == The 2C drugs are orally active at doses of 6 to 150 mg, depending on the drug, and have durations of 3 to 48 hours, also depending on the drug. Several have doses in the range of 10 to 60 mg and durations in the range of 4 to 12 hours. The 2C drugs produce psychedelic effects, such as perceptual enhancement, psychedelic visuals, and euphoria. Some, such as 2C-B, have also been reported to produce some entactogen-like effects, but findings in this area appear to be mixed.
Expressed breastmilk can be stored in freezer storage bags, containers made specifically for breastmilk, a supplemental nursing system, or a bottle ready for use. Parents should avoid using storage containers which contain bisphenol A (BPA). Additionally, use of polyethylene containers have been shown to decrease the immune benefits of breastmilk, including its ability to kill bacteria and the maternal antibodies it contains, by up to 60%.
Sources: en.wikipedia.org
== History == 1939: Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson. 1944: Philip Levine, in the field of hematology, joins Ortho Products to continue his research into the mechanics of the Rh system in human blood. 1997: Ortho Diagnostics Systems and Johnson & Johnson Clinical Diagnostics merge and begin operating as Ortho Clinical Diagnostics. 2001: Ortho becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests. 2006: Ortho launches the first FDA-licensed test to screen blood donations for exposure to Chagas disease. 2014: The Carlyle Group acquires Ortho Clinical Diagnostics for $4.15 billion. 2015: Ortho receives FDA clearance for its ORTHO VISION Analyzer, which automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing laboratories' reliance on manual methods. 2017: FDA approves Ortho's HIV Combo test for the Vitros immunodiagnostic system. The test detects both HIV-1 and HIV-2 antibodies and the p24 antigen, and enables detection of HIV-1 acute infection earlier than previous assays. 2021: Quidel announced it would acquire Ortho Clinical Diagnostics Holdings for $6 billion in cash and stock, increasing the range of COVID-19 antigen and antibody tests the business is able to offer.
=== Morphine === In the 19th century, two major scientific advances were made that had far-reaching effects. Around 1804, German pharmacist Friedrich Sertürner isolated morphine from opium. He described its crystallization, structure, and pharmacological properties in a well-received paper in 1817. Morphine was the first alkaloid to be isolated from any medicinal plant, the beginning of modern scientific drug discovery. The second advance, nearly fifty years later, was the refinement of the hypodermic needle by Alexander Wood and others. Development of a glass syringe with a subcutaneous needle made it possible to easily administer controlled measurable doses of a primary active compound. Morphine was initially hailed as a wonder drug for its ability to ease pain. It could help people sleep, and had other useful side effects, including control of coughing and diarrhea. It was widely prescribed by doctors, and dispensed without restriction by pharmacists. During the American Civil War, opium and laudanum were used extensively to treat soldiers. It was also prescribed frequently for women, for menstrual pain and diseases of a "nervous character". At first it was assumed (wrongly) that this new method of application would not be addictive.
== History == The neurotoxin was reported in 1983 when researchers studied the snake venom for their effects on neuromuscular transmission. Since then, it has contributed to the knowledge about synaptic transmission, cholinergic synapses, and nicotinic acetylcholine receptors (nAChRs). κ-Bungarotoxin is still widely used in research due to its specificity to various nAChRs. The toxin got the kappa in its name as reference to the Latin word kiliaris, which means "related to the eye", from which the ciliary ganglion got its name. Two toxins, named "toxin F" and "bungarotoxin 2.1" were identified by protein sequencing the same way as κ-bungarotoxin.
Sources: en.wikipedia.org
=== Metropolis-coupled MCMC === Metropolis-coupled MCMC algorithm (MC³) has been proposed to solve a practical concern of the Markov chain moving across peaks when the target distribution has multiple local peaks, separated by low valleys, are known to exist in the tree space. This is the case during heuristic tree search under maximum parsimony (MP), maximum likelihood (ML), and minimum evolution (ME) criteria, and the same can be expected for stochastic tree search using MCMC. This problem will result in samples not approximating correctly to the posterior density. The (MC³) improves the mixing of Markov chains in presence of multiple local peaks in the posterior density. It runs multiple (m) chains in parallel, each for n iterations and with different stationary distributions
On 10 February 2021, Camille took part in a demonstration near the Élysée with politicians and activists including Matthieu Orphelin, Cécile Duflot, Marie Toussaint and Cyril Dion. See denounced the "lack of courage" from President Emmanuel Macron, who, according to her, "unraveled" the proposals of the Citizens Convention for Climate when drafting the 2021 loi Climat (Climate Law). On 16 June 2021, she announced that, alongside activist Cyril Dion and MEP Pierre Larrouturou, she was filing a complaint against Jean Castex and four other ministers (Bruno Le Maire, Barbara Pompili, Emmanuelle Wargon and Jean-Baptiste Djebbari) for their inaction in the face of climate change. The French State having already been condemned on numerous occasions (most notably by the Affaire du siècle campaign), they argued that taking individual ministers to court would be a more effective action. Camille is also engaged in campaigns against greenhouse gas emissions, in particular the EACOP, the world's largest heated oil pipeline planned in East Africa by TotalEnergies and the Lützerath mining site in Germany, as well as the exploitation of the seabed. In May 2023, she published Pour un soulèvement écologique : dépasser notre impuissance collective (For an Ecological Uprising: Overcoming our Collective Helplessness). In October 2023, she joined the fight against the planned A69 motorway linking Castres (Tarn) to Toulouse.
The wombat is a marsupial that is often considered to be the marsupial equivalent of the North American groundhog. The fossa of Madagascar looks like a small cat. Fossa have semi-retractable claws. Fossa also has flexible ankles that allow it to climb up and down trees head-first, and also support jumping from tree to tree. Its classification has been controversial because its physical traits resemble those of cats, but is more closely related to the mongoose family, (Herpestidae) or most likely the family Malagasy carnivores family, (Eupleridae). The raccoon dog of Asia looks like the raccoon of North America (hence its scientific name Procyonoides) due to its black face mask, stocky build, bushy appearance, and ability to climb trees. Despite their similarities, it is actually classified as part of the dog family (Canidae). Gliders or passive flight has developed independently in flying squirrels, Australian marsupial, lizards, paradise tree snake, frogs, gliding ants and flying fish and the ancient volaticotherium that lived in the Jurassic Period looked like a flying squirrel, but is not an ancestor of squirrels. Amynodontidae, a family of extinct rhinoceroses that are thought to have looked and behaved like squat, aquatic, hippopotamuses. Trichromatic color vision, separate blue, green and red vision, is found only in a few mammals and came about independently in humans, Old World monkeys and the howler monkeys of the New World, and a few Australian marsupials.
== S == Paul Sabatier (1854–1941), French chemist, 1912 Nobel Prize in Chemistry corecipient Frederick Sanger (1918–2013), 1958 and 1980 Nobel Prize in Chemistry Carl Wilhelm Scheele (1742–1786), Swedish 18th century chemist, discovered numerous elements Christian Friedrich Schönbein (1799–1868), German-Swiss chemist, invented the fuel cell, and discovered gun cotton and ozone Stuart L. Schreiber (born 1956), American chemist, a pioneer in a field of chemical biology Richard R. Schrock (born 1945), 2005 Nobel Prize in Chemistry Peter Schultz (born 1956), American chemist Glenn T. Seaborg (1912–1999), 1951 Nobel Prize in Chemistry Nils Gabriel Sefström (1787–1845), chemist Francesco Selmi (1817–1881), Italian chemist, regarded as one of the founders of colloid chemistry Nikolay Nikolayevich Semyonov (1896–1986), physicist and chemist, 1956 Nobel Prize in Chemistry T. R. Seshadri (1900–1975), Indian chemist, pioneer in plant chemistry K. Barry Sharpless (born 1941), 2001 Wolf Prize in Chemistry, 2001 Nobel Prize in Chemistry Dan Shechtman (born 1941), 2011 Nobel Prize in Chemistry, discovered quasicrystals Patsy O.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.